Effects of agents increasing serotonin transmission on the increase of dopamine metabolism caused by morphine in the rat nucleus accumbens

Effects of fluvoxamine on morphine-induced inhibition of gastrointestinal transit, antinociception and hyperlocomotion in mice

In the present study, the effects of fluvoxamine on the inhibition of gastrointestinal transit, antinociception and hyperlocomotion induced by morphine were investigated in mice. Treatment with morphine (10 mg/kg, subcutaneously (s.c.)) inhibited gastrointestinal transit and hyperlocomotion. These effects were attenuated by fluvoxamine in a dose-dependent manner. On the other hand, morphine (1 mg/kg, s.c.)-induced antinociception was significantly potentiated by fluvoxamine. These results suggest that fluvoxamine combined with morphine may be useful for the treatment of not only depression but also pain in cancer patients without constipation or activation of the mesolimbic dopaminergic system. However, further understanding and clinical studies will be required to confirm this possibility.

Fluoxetine attenuates morphine-induced locomotion and blocks morphine-sensitization

Repeated morphine treatments result in sensitization, an increase in the efficacy of morphine to stimulate locomotor activity. study examined the effects of increasing serotonin (5-hydroxytryptamine, 5-HT) transmission on morphine-sensitization. For five days rats were administered saline or 5.0 mg/kg fluoxetine prior to treatment with saline or 5.0 mg/kg morphine. Twenty-one days later, rats were tested for their locomotor response to 2.0 mg/kg morphine. Fluoxetine treatment attenuated the locomotor activating effect of acute morphine treatments and blocked the sensitized response to the morphine challenge. These results indicate that increased 5-HT transmission attenuates the locomotor stimulating effects of morphine and prevents the development of morphine-sensitization.

Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents

The nucleus accumbens is composed of a core region involved in motor functions and a shell region implicated in emotional and motivational processes. Both of these regions receive serotonin- and dopamine-containing afferents. We examined whether the serotonin innervation or relation to catecholamine (mainly dopamine) axons in the nucleus accumbens shows common features or specializations corresponding to the noted functional differences in core and shell subregions. To address this question, we examined the ultrastructure of serotonin-containing axons and their relation to catecholamine-containing afferents in either the core or shell of the nucleus accumbens. Single coronal sections through the rat forebrain were processed for immunoperoxidase labeling of serotonin and immunogold silver labeling of tyrosine hydroxylase, the catecholamine-synthesizing enzyme. Varicose processes showing peroxidase product for serotonin by light microscopy were confirmed to be axons and terminals by electron microscopy. In a quantitative analysis of serotonin-immunoreactive terminals forming one or more contacts in single sections, some common features were observed. For the core (n = 120) and the shell (n = 82), 41% formed synaptic junctions with unlabeled dendrites, 75% were in apposition with unlabeled terminals, which often formed asymmetric junctions, and 20% were in apposition with axons or terminals containing tyrosine hydroxylase. Thus, in both the core and shell of the nucleus accumbens, serotonin terminals synapse on postsynaptic neurons and are likely to modulate or be modulated by presynaptic interactions with excitatory axons forming asymmetric junctions and by catecholaminergic afferents. Marked differences in the morphology of serotonin axons were also seen in the core versus shell of the nucleus accumbens. By light microscopy, serotonin-immunoreactive axons were thicker and more varicose than those found in the core. Ultrastructural analysis confirmed that, in contrast to the core, serotonin-immunoreactive axons and terminals in the shell were larger in cross-sectional diameter size (0.7 micron vs. 0.3 micron). Additionally, serotonin axon terminals in the shell contained more numerous immunoreactive large dense core vesicles and more frequently formed symmetric as opposed to asymmetric contacts with dendrites. The larger size and more numerous dense core vesicles in serotonin-immunoreactive terminals in the shell support the concept that serotonin or co-existing neurotransmitter may be more tonically released in the shell versus core of the nucleus accumbens.

Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF

The repeatedly observed strong positive correlation between 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) in human cerebrospinal fluid (CSF) prompted an investigation to see if conclusions concerning possible interactions between brain serotonin and dopamine turnover could be reached from human CSF concentrations of these acid metabolites. CSF data from patients with depressive disorders diagnosed according to the RDC from Sweden (n = 140) and from the National Institute of Mental Health (n = 35) were used to test structural hypotheses by two statistical approaches--LISREL analysis and logistic regression. Results from both men and women were unequivocal: 5HIAA "controls" HVA, interpretable as a regulatory action of serotonin turnover on dopamine turnover. In women, only 5HIAA was affected by age, height and body size (higher in elderly, short and stout women); no similar relationships were seen in males. The concept of a serotonergic regulation of dopamine turnover was tested on brain punch analyses of serotonin and dopamine and their metabolites in two sets of dogs in a large number of brain areas. Results confirm a facilatory effect of serotonin on indices of dopamine turnover in many brain regions, especially brain stem and hypothalamus. The animal data validate the data analytic approach in humans.